Why the study?
Yiqi Shexue formula is traditionally used to treat primary immune thrombocytopenia, but its mechanisms of action and molecular targets are not clear.
Population
ITP patients and healthy individuals
Design
Network pharmacology and bioinformatic analysis
Key result
Network pharmacology analysis identified 183 target genes and 24 pathways, including MDM2, TP53, and MAPK signaling, as key mechanisms for Yiqi Shexue formula in treating primary immune thrombocytopenia.
Authors
Loading...
Identifies potential YQSX targets in ITP; leaves open efficacy confirmation in randomized trials.
Network pharmacology analysis suggests that Yiqi Shexue formula may treat primary immune thrombocytopenia by regulating immunological function through specific biological processes and pathways, with MDM2 as a core target gene.
Jiang et al. (2019) studied Primary immune thrombocytopenia (ITP). Yiqi Shexue formula (YQSX) was evaluated on Identification of candidate targets and pathways for YQSX against ITP. Network pharmacology analysis identified 183 target genes and 24 pathways, including MDM2, TP53, and MAPK signaling, as key mechanisms for Yiqi Shexue formula in treating primary immune thrombocytopenia.